Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine E R Smith

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|May 16, 2022
Validating chemoimmunotherapy in small-cell lung cancerKatherine E R Smith, Aaron S Mansfield
Clinical Chemistry|January 4, 2024
Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint InhibitorsKatherine E R Smith, Svetomir N Markovic
Scientific Reports|April 16, 2025
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelinKatherine E R Smith, Jennifer R Ayers-Ringler, Jacob J Orme, et al.
JTO Clinical and Research Reports|January 1, 2024
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With AtezolizumabKatherine E R Smith, Stephanie L Pritzl, Wei Yu, et al.
Journal of Midwifery & Women'S Health|February 1, 2021
Knowledge of and Attitudes Toward Perinatal Home Visiting in Women with High-Risk PregnanciesJennifer L Barkin, Joan Rosen Bloch, Katherine E R Smith, et al.
FEBS Open Bio|February 19, 2022
MAP kinases differentially bind and phosphorylate NOS3 via two unique NOS3 sitesXzaviar K V Solone, Amber L Caldara, Brady Wells, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2026
Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagementShinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, et al.
JCO Precision Oncology|November 22, 2024
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK AlterationsKatherine E R Smith, Aldo A Acosta-Medina, Surendra Dasari, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesotheliomaAaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|May 16, 2022
Validating chemoimmunotherapy in small-cell lung cancerKatherine E R Smith, Aaron S Mansfield
Clinical Chemistry|January 4, 2024
Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint InhibitorsKatherine E R Smith, Svetomir N Markovic
Scientific Reports|April 16, 2025
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelinKatherine E R Smith, Jennifer R Ayers-Ringler, Jacob J Orme, et al.
JTO Clinical and Research Reports|January 1, 2024
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With AtezolizumabKatherine E R Smith, Stephanie L Pritzl, Wei Yu, et al.
Journal of Midwifery & Women'S Health|February 1, 2021
Knowledge of and Attitudes Toward Perinatal Home Visiting in Women with High-Risk PregnanciesJennifer L Barkin, Joan Rosen Bloch, Katherine E R Smith, et al.
FEBS Open Bio|February 19, 2022
MAP kinases differentially bind and phosphorylate NOS3 via two unique NOS3 sitesXzaviar K V Solone, Amber L Caldara, Brady Wells, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2026
Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagementShinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, et al.
JCO Precision Oncology|November 22, 2024
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK AlterationsKatherine E R Smith, Aldo A Acosta-Medina, Surendra Dasari, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesotheliomaAaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, et al.
Pageof 1